AEterna Zentaris Inc. (AEZS): Another partnership for Zoptrex,now for...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	51
Posts	4564
Boards Moderated	0
Alias Born	12/14/2009

alexander77

Re: doogdilinger post# 15313

Friday, 07/01/2016 8:52:41 AM

Friday, July 01, 2016 8:52:41 AM

Another partnership for Zoptrex,now for Taiwan and Southasia!!

Aeterna Zentaris Inc. (AEZS) (AEZ.TO) (the “Company”) and Orient EuroPharma Co., Ltd. (“OEP”) today announced the signing of an exclusive license agreement between the Company and Cyntec Co., Ltd., an affiliate of OEP (“Cyntec”), for the Company’s lead anti-cancer compound, Zoptrex™ (zoptarelin doxorubicin), for the initial indication of endometrial cancer, for Taiwan and nine countries in Southeast Asia (the “Territory”). Zoptrex™, a novel synthetic peptide carrier linked to doxorubicin as a New Chemical Entity (NCE), is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer. The Company expects to complete the Phase 3 clinical trial in the third quarter of 2016 and, if the results of the trial warrant doing so, to file a new drug application for Zoptrex™ in the first half of 2017.

http://finance.yahoo.com/news/aeterna-zentaris-orient-europharma-co-123000314.html